EC Number   |
Disease |
PubMed ID  |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.24.82 | Neoplasms |
10376599 |
Control of organ shape by a secreted metalloprotease in the nematode Caenorhabditis elegans. |
causal interaction
unassigned |
3
0 |
| 3.4.24.82 | Colonic Neoplasms |
10811842 |
ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. |
ongoing research
unassigned |
2
0 |
| 3.4.24.82 | Arthritis |
10827174 |
The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. |
unassigned |
0 |
| 3.4.24.82 | Chondrosarcoma |
11068207 |
Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions. |
ongoing research
unassigned |
2
0 |
| 3.4.24.82 | Osteosarcoma |
11108265 |
ADAMTS-1: A cellular disintegrin and metalloprotease with thrombospondin motifs is a target for parathyroid hormone in bone. |
therapeutic application
unassigned |
1
0 |
| 3.4.24.82 | Glioma |
11217446 |
Tumor cell-matrix interaction: pericellular matrix degradation and metastasis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
4
1 |
| 3.4.24.82 | Joint Diseases |
11254106 |
Characterization of 5'-flanking region of human aggrecanase-1 (ADAMTS4) gene. |
causal interaction
therapeutic application
unassigned |
3
1
0 |
| 3.4.24.82 | Arthritis |
11311239 |
Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.4.24.82 | Osteoarthritis |
11325536 |
Matrix metalloproteinase-1, -3, -13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis. |
unassigned |
0 |
| 3.4.24.82 | Chondrosarcoma |
11796708 |
Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. |
ongoing research
therapeutic application
unassigned |
2
1
0 |
